CN118660911A - 人间皮素结合剂 - Google Patents

人间皮素结合剂 Download PDF

Info

Publication number
CN118660911A
CN118660911A CN202280090785.9A CN202280090785A CN118660911A CN 118660911 A CN118660911 A CN 118660911A CN 202280090785 A CN202280090785 A CN 202280090785A CN 118660911 A CN118660911 A CN 118660911A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
seq
binding agent
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280090785.9A
Other languages
English (en)
Chinese (zh)
Inventor
A·弗里德曼
半田雅久
谢仲明
苏佳塔·辛格
萨巴·塔布里兹法尔德
桑德拉·伊莎贝尔·凡内加斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Original Assignee
Merck Sharp and Dohme BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme BV filed Critical Merck Sharp and Dohme BV
Publication of CN118660911A publication Critical patent/CN118660911A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280090785.9A 2021-12-10 2022-12-09 人间皮素结合剂 Pending CN118660911A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163288162P 2021-12-10 2021-12-10
US63/288,162 2021-12-10
PCT/US2022/081253 WO2023108114A2 (en) 2021-12-10 2022-12-09 Human mesothelin binders

Publications (1)

Publication Number Publication Date
CN118660911A true CN118660911A (zh) 2024-09-17

Family

ID=86731328

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280090785.9A Pending CN118660911A (zh) 2021-12-10 2022-12-09 人间皮素结合剂

Country Status (8)

Country Link
EP (1) EP4444757A4 (https=)
JP (1) JP2025501452A (https=)
KR (1) KR20240114766A (https=)
CN (1) CN118660911A (https=)
AU (1) AU2022407541A1 (https=)
CA (1) CA3239553A1 (https=)
MX (1) MX2024007054A (https=)
WO (1) WO2023108114A2 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2526355T3 (es) * 2007-10-01 2015-01-09 Bristol-Myers Squibb Company Anticuerpos humanos que se adhieren a mesotelina, y usos de los mismos
BR112013014527A2 (pt) * 2010-12-20 2017-03-07 Genentech Inc anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina
WO2014004549A2 (en) * 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
WO2018209304A1 (en) * 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
GB201811450D0 (en) * 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
SG11202106764YA (en) * 2018-12-27 2021-07-29 Gigagen Inc Anti-ctla-4 binding proteins and methods of use thereof
KR20220047536A (ko) * 2019-04-01 2022-04-18 레이크파르마, 인코퍼레이티드 면역반응의 조절 및 질병의 치료를 위한 btla-결합(cd272) 항체

Also Published As

Publication number Publication date
WO2023108114A2 (en) 2023-06-15
JP2025501452A (ja) 2025-01-22
EP4444757A4 (en) 2026-04-15
AU2022407541A1 (en) 2024-06-13
WO2023108114A3 (en) 2024-04-04
CA3239553A1 (en) 2023-06-15
EP4444757A2 (en) 2024-10-16
MX2024007054A (es) 2024-09-04
KR20240114766A (ko) 2024-07-24

Similar Documents

Publication Publication Date Title
US11274142B2 (en) Fusion protein containing TGF-β receptor and medicinal uses thereof
US20160009824A1 (en) Tetravalent bispecific antibodies
JP7397882B2 (ja) 二重特異性抗体及びその調製方法、使用
GB2519786A (en) Multivalent antigen-binding protein molecules
US20250051467A1 (en) Fap/cd40 binding molecule and medicinal use thereof
EP4467571A1 (en) Anti-cd3 and anti-cd20 bispecific antibody and use thereof
CN121758617A (zh) 结合4-1bb和肿瘤相关抗原的抗体构建体以及其用途
JP7076571B2 (ja) 細胞エンゲージ結合分子
EP4155318A1 (en) Bispecific antibody and use thereof
CA3231320A1 (en) Protein specifically binding to pd-1 and pharmaceutical use thereof
KR20240042009A (ko) 항-cd38 항체, 항-cd3 항체, 및 이중특이적 항체 및 이의 용도.
CN117881702A (zh) 一种cd16抗体及其应用
KR20210132664A (ko) 항pd-l1 항체 및 그의 용도
WO2022121941A1 (zh) 抗人msln的抗体及其用途
EP3647323A1 (en) Anti-gitr antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CN119698294A (zh) 结合γ-δT细胞受体的变体抗体
EP4624492A1 (en) Anti-ccr8 antibody and use thereof
AU2021307516B2 (en) Anti-CLDN-18.2 antibody and use thereof
CN118660911A (zh) 人间皮素结合剂
US20240002533A1 (en) Arginase 1 binders for inhibiting arginase 1 activity
HK40116952A (zh) 人间皮素结合剂
WO2026060339A1 (en) Human claudin 18.2 binders and uses thereof
CN116323658A (zh) 靶向PD-1或PD-L1和TGF-β的双功能蛋白及其医药用途
CN120917047A (zh) 抗cldn6和抗cd3多特异性抗体及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40116952

Country of ref document: HK